Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leqembi
Biogen's monoclonal antibody for Alzheimer's disease.
Pharma
Trump's tariffs, Leqembi, Kyowa Kirin—Fierce Pharma Asia
U.S. pharma tariffs are expected "in the next months or two." Leqembi won approval in the EU. Kyowa Kirin completed a biologics plant. And more.
Angus Liu
Apr 18, 2025 9:25am
Eisai and Biogen's Alzheimer's med Leqembi approved in Europe
Apr 16, 2025 7:52am
Eisai lays out road map to blockbusterland for Leqembi
Mar 25, 2025 11:08am
Trump policy, Pfizer, CMIC—Fierce Pharma Asia
Mar 7, 2025 8:05am
NICE again rejects Alzheimer's drugs from Lilly and Biogen/Eisai
Mar 6, 2025 10:47am
CHMP again backs Leqembi amid flurry of approval recommendations
Feb 28, 2025 10:30am
